Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Shareholder vote
confidence 75%
filed 2026-06-25
EX-99.1
The exhibit announces results of the 2026 Annual General Meeting held June 25, 2026, disclosing shareholder approval of six directors (including new Chair Paul Andre Huet and Lead Director Tamara Brown), auditor appointment (KPMG LLP), and equity plan approvals. The departure of director William Hayden and engagement of ICP as market maker are secondary announcements bundled with the primary AGM results disclosure. The core event is shareholder vote results under Item 5.07 equivalent.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder vote results from BlackBerry's Annual and Special Meeting of Shareholders held on June 25, 2026, covering seven matters: election of eight directors, re-appointment of auditors (PricewaterhouseCoopers LLP), approval of DSU Plan entitlements, amendments to the Employee Share Purchase Plan, advisory votes on executive compensation and say-on-pay frequency, and a shareholder proposal on by-law amendments. The filing presents detailed voting tallies for each matter, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
This is a disclosure of shareholder vote results at a special meeting held on June 24, 2026, where shareholders approved a proposal to authorize and approve a strategic transaction with Apotex involving the sale of Cumberland's FDA-approved commercial products and related assets under an Asset Purchase Agreement. The filing explicitly reports voting tallies (10,492,455 for, 15,904 against, 1,267 abstentions) and quorum information, which is the core content of Item 5.07. While the underlying transaction is material M&A activity, the 8-K Item 5.07 section itself is reporting the vote results, making shareholder_vote_results the appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder voting results from Mobileye's June 18, 2026 annual meeting of stockholders. The filing reports the outcomes of three proposals: election of nine directors (all elected), ratification of the independent auditor (approved), and an advisory vote on executive compensation (approved). Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly presents voting tallies with vote counts for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
NextCure held its Annual Meeting of Stockholders on June 18, 2026, with shareholders voting on four proposals: election of two Class I directors (Anne Borgman and John G. Houston), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2019 Omnibus Incentive Plan. The filing discloses detailed voting results for all four proposals.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
The exhibit discloses results of GDS Holdings' 2026 Annual General Meeting held on June 25, 2026, with all seven shareholder resolutions passed, including re-election and election of directors (Wojtaszek, Zhang, Chen), extension of the 2016 Equity Incentive Plan, confirmation of KPMG Huazhen LLP as auditor, and authorization for board discretion on equity issuances up to 30% of existing share capital. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, material because it confirms director elections and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure reports the results of Protalix's 2026 Annual Meeting of Stockholders held on June 25, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, approval of an amended stock incentive plan increasing available shares by 3.5 million, and ratification of the independent auditor (Kesselman & Kesselman/PwC). The detailed vote tallies for each proposal are provided, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure reports the final voting results from Gain Therapeutics' June 24, 2026 annual meeting of stockholders, including the election of seven directors and ratification of Ernst & Young AG as independent auditor. The detailed vote tallies for each nominee and the auditor ratification proposal are the core content, matching the shareholder_vote_results event type precisely.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure reports the results of Journey Medical's 2026 Annual Meeting held on June 24, 2026, including voting outcomes for two proposals: (i) election of six directors and (ii) ratification of KPMG LLP as independent auditor. The filing provides detailed vote tallies for each director and the auditor ratification, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder voting results from a special meeting held on June 25, 2026. The filing reports the vote tallies for two proposals: (1) approval of a reverse stock split amendment with a ratio range of 1-for-5 to 1-for-25, which passed with 26,898,163 votes for versus 751,966 against, and (2) approval of an adjournment proposal, which also passed. A reverse stock split is a material capital structure event that affects all shareholders, making the voting results material to investors.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
This press release discloses the results of Cellectis' shareholders general meeting held on June 25, 2026, reporting that resolutions 1–29 were adopted and resolution 30 was rejected, with approximately 55.84% of voting rights exercised. This is a direct disclosure of shareholder vote results, matching Item 5.07 of the 8-K taxonomy and the `shareholder_vote_results` event type. The outcome of shareholder votes on board-recommended resolutions is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-06-25
The 6-K discloses results of Silicom's Annual General Meeting of Shareholders held June 3, 2026, including approval of director re-election, executive salary increases, auditor appointment, and notably the rejection and subsequent override of RSU grants to the CEO and Chairman. The override of shareholder rejection of executive compensation and the conditional approval of RSUs tied to a $83 million revenue threshold are material governance and compensation events affecting investor assessment of executive incentives and board authority.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure reports the results of Aeva Technologies' 2026 Annual Meeting of Stockholders held on June 18, 2026, including voting outcomes for the election of Class II directors (Hrach Simonian and Stephen Zadesky) and ratification of Deloitte & Touche LLP as independent auditor. The filing presents vote tallies (FOR, AGAINST, WITHHOLD, ABSTAIN, and broker non-votes) for each proposal, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-25
EX-99.1
This press release discloses the results of GigaMedia's Annual General Meeting held on 25 June 2026, presenting poll results for five resolutions including adoption of audited financial statements, approval of auditors, directors' remuneration, share allotment authority, and share purchase mandate. The detailed voting tallies and percentages for each resolution are the core content, matching the shareholder_vote_results taxonomy precisely.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
The 6-K discloses the results of ORIX Corporation's 63rd Annual General Meeting of Shareholders held on June 23, 2026, including voting outcomes on three proposals: amendments to Articles of Incorporation (two proposals) and election of ten directors. The filing presents detailed voting tallies (approvals, disapprovals, abstentions, and approval rates) for each matter, which is the core content of a shareholder vote results disclosure. This is material because director elections and bylaw amendments affect governance and investor rights.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 90%
filed 2026-06-25
Item 5.07
Shareholders approved an amendment to the Company's Articles of Association extending the deadline for completing a business combination to 27 months from the IPO closing (December 23, 2024), with 11,660,851 shares voting in favor and 1,974,523 against; 9,339,529 ordinary shares were subsequently redeemed at approximately $10.62 per share, resulting in approximately $99.5 million in redemptions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This 8-K Item 5.07 discloses the results of the Company's 2026 Annual Meeting of Stockholders held on June 23, 2026, including voting outcomes for two proposals: (1) election of directors Alexander Duka and Gary Kovacs as Class I directors, and (2) ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026. The detailed vote tallies (For, Against, Withhold, Abstain, Broker Non-Votes) are the core disclosure required by Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
SmartStop held its 2026 Annual Meeting of Stockholders on June 23, 2026, with shareholders voting on four proposals: election of six directors, advisory vote on executive compensation, frequency of future advisory votes on compensation, and ratification of BDO USA as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
ACRES Commercial Realty Corp. held its 2026 Annual Meeting of Stockholders on June 22, 2026, with voting results on five proposals: election of nine directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as auditor, approval of approximately 7.5 million shares for the ACRES Capital Corp. merger, and adoption of the 2026 Omnibus Equity Incentive Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for two proposals: election of three directors (H. Michael Schwartz, Stephen G. Muzzy, and Alexander S. Vellandi) and ratification of BDO USA, P.C. as independent auditor. All three directors were elected and the auditor appointment was ratified by substantial majorities, making this a material governance event that investors rely on to assess board composition and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder vote results from the June 24, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: election of nine directors, ratification of Deloitte & Touche as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (shares for, against, withheld, abstained, and broker non-votes) for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
This exhibit presents the complete voting results from Cellectis S.A.'s Combined General Meeting of Shareholders, detailing 30 resolutions with vote tallies (For, Against, Vote Withhold), percentages, and quorum information. The resolutions cover material matters including approval of annual and consolidated financial statements, board director renewals, share buyback authorization, multiple capital increase delegations, and equity compensation authorizations. This is a classic shareholder_vote_results disclosure required under Item 5.07 equivalent for foreign private issuers.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure presents the results of Fulcrum's 2026 annual stockholder meeting held on June 24, 2026, including election of three Class I directors (Sonja Banks, Alan Ezekowitz, Colin Hill), advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The filing directly reports voting outcomes on these material governance matters, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 discloses the final voting results from Coya Therapeutics' Annual Meeting of Stockholders held on June 25, 2026, including the election of two Class I directors (Secretary Wilbur Ross and Dieter Weinand) and ratification of Weaver and Tidwell, L.L.P. as independent auditor. The detailed vote tallies (For, Withheld, Broker Non-Votes, Against, Abstain) are the core disclosure required under Item 5.07 for shareholder meeting outcomes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from ARS Pharmaceuticals' 2026 Annual Meeting held on June 24, 2026. The filing reports voting outcomes on four proposals: election of three Class III directors (Saqib Islam, Phillip Schneider, and Laura Shawver), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (determined to be annual). These are standard annual meeting matters that materially inform investors about board composition and governance preferences.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder voting results from Semnur Pharmaceuticals' 2026 Annual Meeting of Stockholders held on June 25, 2026. The filing reports the outcomes of four proposals: election of a Class I director (Jay Chun, M.D., Ph.D.), ratification of Pipara & Co LLP as independent auditor, approval of the 2025 Equity Incentive Plan, and approval of the 2025 Employee Stock Purchase Plan, with detailed vote tallies for each. This is a standard Item 5.07 disclosure of shareholder meeting results, which is material to investors as it confirms governance decisions and equity plan approvals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
Spero Therapeutics held its Annual Meeting on June 23, 2026, with stockholders voting on five matters: reelection of Class III directors (Milind Deshpande and Kathleen Tregoning), ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, amendment to increase authorized common shares from 120 million to 240 million, and approval of the 2026 Stock Incentive Plan authorizing up to 12,895,866 shares for compensatory purposes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure presents the final voting results from the Company's 2026 Annual Meeting of Stockholders, including the election of three directors (H. Michael Schwartz, Brent Chappell, and Stephen G. Muzzy) and ratification of BDO USA, P.C. as the independent auditor. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
The 6-K discloses results of the Company's Annual General Meeting of Shareholders held on June 23, 2026, at which shareholders approved six proposals including re-election of directors (David Milch and Ruth Alon), re-approval of the compensation policy, re-appointment of Uzi Sofer as Chairman, approval of his compensation package, extension of option terms, and re-appointment of the independent auditor. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, and the approval of executive compensation and auditor re-appointment are material governance matters.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
This press release announces the results of Mega Matrix Inc.'s 2026 Annual General Meeting held on June 22, 2026. Shareholders approved four discrete proposals: (1) election of four board directors, (2) a 20-for-1 share consolidation, (3) amended memorandum and articles of association, and (4) appointment of Audit Alliance LLP as independent auditor. The disclosure of shareholder vote outcomes on these material governance and capital structure matters is a classic shareholder_vote_results event, material to investors assessing the company's governance and capitalization.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
The filing discloses results of Chicago Atlantic BDC's 2026 annual meeting of stockholders held on June 24, 2026, under Item 5.07. Two matters were voted upon: (1) re-election of two Class 2 directors (Americo Da Corte and Tracey Brophy Warson), and (2) ratification of BDO USA, P.C. as independent auditor. Vote tallies are provided for each proposal, making this a clear shareholder vote results disclosure material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder vote results from Ispire Technology's Annual Meeting of Stockholders held on June 23, 2026. The filing reports voting outcomes for two proposals: (1) election of five directors (Tuanfang Liu, Jiangyan Zhu, Christopher Robert Burch, Brent Cox, and John Fargis) for one-year terms, and (2) ratification of Marcum Asia LLP as the independent auditor for fiscal year ending June 30, 2026. The detailed vote tallies (votes for, against, abstained, and broker non-votes) are provided for each nominee and proposal, which is the standard format for Item 5.07 disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 discloses the results of an extraordinary general meeting of RAAQ shareholders held on June 25, 2026, where shareholders voted on and approved two critical proposals: (1) the Business Combination Agreement with IQM Quantum Computers Oyj, and (2) the Merger and Plan of Merger. The voting results show overwhelming approval (13,687,335 for vs. 800,760 against on the Business Combination Proposal), representing a material M&A transaction that will result in RAAQ merging into a subsidiary of IQM. This is a classic shareholder vote result disclosure under Item 5.07, and the underlying business combination is material to investors.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
This exhibit is a news release announcing the results of Cardiol Therapeutics' Annual General Meeting of Shareholders held on June 24, 2026. The disclosure reports shareholder voting outcomes on director elections (eight directors elected with vote percentages ranging from 96.24% to 99.19%) and auditor appointment (BDO Canada LLP). This is a classic shareholder_vote_results disclosure, material because it confirms the composition of the board and auditor for the ensuing fiscal year.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
This exhibit is a news release announcing voting results from Nexa Resources' Annual General Meeting and Extraordinary General Meeting held on June 25, 2026. The document discloses shareholder votes on multiple resolutions including approval of annual accounts, board member reelections, auditor appointment, and authorized share capital amendments. The release also announces a share premium reimbursement of approximately US$0.132136 per common share (US$17.5 million total), payable August 11, 2026. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital reimbursement decision is material to investors.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-25
EX-99.1
This exhibit discloses the voting results from Nexa Resources' Annual General Meeting and Extraordinary General Meeting of Shareholders held on June 25, 2026. The document presents tabulated vote counts for multiple resolutions including approval of annual accounts, consolidated financial statements, share premium distribution, board discharge, director reelections, board remuneration, auditor reappointment, and amendments to the Articles of Association. This is a classic shareholder_vote_results disclosure documenting the outcomes of shareholder votes at the company's annual and extraordinary meetings.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
eHealth held its Annual Meeting of Stockholders on April 20, 2026, with voting results on four proposals: election of two Class II directors (Prama Bhatt and Beth A. Brooke), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2024 Equity Incentive Plan increasing the share pool by 1,300,000 shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
Lululemon held its 2026 Annual Meeting of stockholders with voting results on five matters: election of three Class I directors (Bergh, Bracey, and List), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2023 Equity Incentive Plan to increase share reserve, and approval of a stockholder proposal for board declassification. All proposals passed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This Item 5.07 disclosure reports the results of Omeros' 2026 Annual Meeting of Shareholders held on June 18, 2026, including voting outcomes on four matters: election of three Class II directors (Thomas J. Cable, Peter A. Demopulos, M.D., and Diana T. Perkinson, M.D.), advisory approval of named executive officer compensation, approval of the Amended and Restated Omnibus Incentive Compensation Plan, and ratification of Ernst & Young LLP as independent auditor. The filing presents detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
At the June 24, 2026 Annual Meeting, shareholders voted on the election of directors for both Class A and Class B Common Stock (Proposal 1) and ratification of independent auditor Kerber, Eck & Braeckel LLP (Proposal 2), with detailed vote tallies reported for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder voting results from the Annual Meeting of Stockholders held on June 25, 2026, filed under Item 5.07. The filing reports the final voting tallies for two proposals: (1) election of five directors (Jon Isaac, Tony Isaac, Greg LeClaire, Dennis Gao, and Tyler Sickmeyer) with votes for, withheld, and broker non-votes, and (2) ratification of Frazier & Deeter, LLC as the independent accounting firm. These are routine but material governance matters that affect the composition of the board and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 7.01
The filing discloses the results of a special meeting of shareholders held on June 25, 2026, where shareholders approved the reorganization of FCT (First Trust Senior Floating Rate Income Fund II) with and into First Trust Flexible Income ETF (FFLX). This is a shareholder vote result on a material corporate action—a fund reorganization/merger—that will result in the transfer of all assets and liabilities and the exchange of shares. The disclosure explicitly states "Shareholders of FCT...have approved the reorganization," which is the core shareholder vote result being reported.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
The filing discloses results of NextBoat Inc.'s annual meeting of stockholders held on June 24, 2026, under Item 5.07. Three proposals were voted upon: election of seven directors (all elected with overwhelming support), ratification of M&K CPAS PLLC as independent auditor, and approval of the First Amended and Restated 2025 Equity Incentive Plan. These are routine shareholder vote results that materially inform investors of governance and compensation decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-06-25
The filing discloses results of Fabric.AI's June 18, 2026 annual stockholder meeting under Item 5.07, including voting outcomes on seven proposals: director elections, approval of dilutive equity issuances (Series K and J preferred stock and multiple warrant tranches), auditor ratification, incentive plan amendment, say-on-pay votes, and adjournment authority. The detailed voting tallies and board determination regarding say-on-frequency voting constitute material shareholder vote results that would affect investor assessment of governance and capital structure decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
This Item 5.07 discloses the results of an annual shareholder meeting held on June 18, 2026, including voting outcomes on three proposals: election of six directors (with Scott I. Ross failing to receive majority support but being reaffirmed by the Board), ratification of KPMG LLP as auditor, and advisory approval of named executive officer compensation. The detailed vote tallies and Board's decision to retain Mr. Ross despite his failed election constitute material shareholder voting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder vote results from Liberty Global's June 23, 2026 annual general meeting, covering four proposals: election of three directors (Miranda Curtis CMG, J David Wargo, Anthony G. Werner), appointment of KPMG LLP as auditors, advisory approval of named executive officer compensation, and frequency of future say-on-pay votes. The filing provides detailed vote tallies and confirms all resolutions passed, with the say-on-pay frequency set at three years. This is a quintessential Item 5.07 disclosure and is material to investors as it documents shareholder approval of board composition and governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from Synchrony Financial's 2026 Annual Meeting held on June 24, 2026. The filing reports detailed vote tallies for three proposals: election of all 12 directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure that affects investor understanding of board composition and shareholder sentiment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder vote results from AquaBounty's Annual Meeting of Stockholders held on June 23, 2026, covering five proposals: director elections, auditor ratification, reverse stock split authorization, executive compensation approval, and meeting adjournment. The filing presents final voting tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures. The reverse stock split authorization (Proposal 3) is particularly material as it grants the Board discretion to effect a 1-for-5 to 1-for-20 reverse split by July 31, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-25
Item 5.07
This is a clear disclosure of shareholder voting results from Red Cat Holdings' 2026 Annual Meeting held on June 18, 2026. The filing reports results for three proposals: election of five directors, ratification of KPMG LLP as independent auditor, and a non-binding advisory vote on executive compensation. The disclosure includes vote counts (For, Against, Withheld, Abstentions, Broker Non-Votes) for each proposal, which is the hallmark of Item 5.07 shareholder vote results. Notably, Proposal 3 (say-on-pay) failed to receive majority support, which is material information for investors assessing governance and compensation alignment.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-25
EX-99.1
The exhibit discloses the results of Valneva's Annual General Meeting held on June 25, 2026, including shareholder approval of all Board-recommended resolutions (2025 financial statements, board authorizations, office relocation) and reappointment of five Board members. Additionally, Dr. Gerd Zettlmeissl was appointed as Chair of the Board following the AGM, succeeding Anne-Marie Graffin. This is a material governance event affecting board leadership and shareholder-approved strategic decisions.
View raw filing on EDGAR →